#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14768	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2123	692.2	0	.	n	.	0	A69G	SNP	69	69	A	349	349	G	803	G,A	757,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14768	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2123	692.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1730	1730	T	806	T,C	743,3	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14768	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2123	692.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1464	1464	C	857	C,T	799,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27066	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3612	747.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1746	1746	A	925	A,T,G	859,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27066	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3612	747.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2380	2380	C	916	C,T,A,G	829,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27066	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3612	747.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2454	2454	A	892	A	847	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27066	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3612	747.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3006	3006	C	840	C	792	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	1896	folP	852	852	99.88	folP.l15.c4.ctg.1	1570	120.3	0	.	p	.	0	E151K	NONSYN	451	453	GAA	878	880	AAA	163;160;163	A;A;A	155;154;155	.	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	1896	folP	852	852	99.88	folP.l15.c4.ctg.1	1570	120.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1109	1111	AGC	181;180;177	A;G;C	168;167;159	folP.WHO_K_01359c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5458	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3313	164.0	1	SNP	p	S91F	0	.	.	271	273	TCC	539	541	TCC	183;185;184	T;C,T;C	170;171,2;171	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5458	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3313	164.0	1	SNP	p	D95N	0	.	.	283	285	GAC	551	553	GAC	178;180;183	G;A,G;C	168;166,2;173	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5458	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3313	164.0	1	SNP	p	D95G	0	.	.	283	285	GAC	551	553	GAC	178;180;183	G;A,G;C	168;166,2;173	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1632	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1323	122.8	1	SNP	p	G45D	0	.	.	133	135	GGC	564	566	GGC	207;206;206	G;G;C	198;194;197	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	826	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1024	80.4	0	.	n	.	0	A197.	DEL	197	197	A	607	607	A	187	A	176	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5678	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2807	201.1	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1566	1568	GCA	254;253;254	G;C,G;A	236;234,1;233	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5678	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2807	201.1	1	SNP	p	D86N	0	.	.	256	258	GAC	519	521	GAC	252;248;250	G,A;A;C	232,1;230;232	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5678	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2807	201.1	1	SNP	p	S87R	0	.	.	259	261	AGT	522	524	AGT	251;249;249	A;G;T	231;230;231	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5678	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2807	201.1	1	SNP	p	S87I	0	.	.	259	261	AGT	522	524	AGT	251;249;249	A;G;T	231;230;231	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5678	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2807	201.1	1	SNP	p	S87W	0	.	.	259	261	AGT	522	524	AGT	251;249;249	A;G;T	231;230;231	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5678	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2807	201.1	1	SNP	p	S88P	0	.	.	262	264	TCC	525	527	TCC	249;251;253	T;C;C	230;233;237	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4152	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2587	159.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1525	1527	GGC	210;205;204	G;G;C	199;195;193	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3966	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	160.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1210	1212	GCA	202;203;204	G;C;A	192;194;195	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3966	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	160.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1213	1215	ATC	207;206;212	A;T;C	199;198;202	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3966	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	160.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1225	1227	GTG	204;202;201	G;T;G	191;190;189	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3966	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	160.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1225	1227	GTG	204;202;201	G;T;G	191;190;189	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3966	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	160.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1729	1731	ACC	187;187;188	A,G;C;C	170,1;178;176	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3966	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	160.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1783	1785	GCG	188;188;182	G;C;G	162;149;147	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3966	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	160.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1783	1785	GCG	188;188;182	G;C;G	162;149;147	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3966	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	160.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1906	1908	GGC	164;165;165	G;G;C	159;161;160	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3966	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	160.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1915	1917	GGC	162;161;161	G;G;C	151;153;153	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3966	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	160.7	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1933	1935	CTG	155;157;155	C,G;T;G	121,5;118;118	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5876	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3281	178.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1680	1682	CCG	237;237;235	C;C;G	212;217;211	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2120	porA	1146	1146	99.65	porA.l15.c30.ctg.1	1988	106.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	584	584	C	151	C	146	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	T26A	NONSYN	76	78	ACC	470	472	GCC	236;236;235	G;C;C	213;211;210	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	506	508	GAA	206;202;204	G;A;A	192;189;188	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	K41G	NONSYN	121	123	AAA	515	517	GGC	200;201;202	G,A;G,A;C,A	190,1;189,1;188,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	T89S	NONSYN	265	267	ACC	659	661	AGC	244;242;245	A;G;C	235;227;230	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	.	MULTIPLE	358	359	AA	751	752	CG	209;212	C,T;G,A	201,1;200,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	.	MULTIPLE	361	362	GA	754	756	CAG	213;218;218	C,G;A;G,A	201,1;205;204,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	N122K	NONSYN	364	366	AAC	758	760	AAA	218;216;218	A;A;A,C	209;207;206,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	785	787	TAT	227;224;228	T;A,C,T;T	205;202,1,1;201	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	N134E	NONSYN	400	402	AAT	794	796	GAG	228;230;230	G,A;A;G,T	209,1;210;208,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	V135F	NONSYN	403	405	GTG	797	799	TTT	230;231;230	T,G;T;T,G	208,1;210;211,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	G140K	NONSYN	418	420	GGA	812	814	AAA	225;229;226	A,G;A,G;A	205,1;210,1;209	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	K143E	NONSYN	427	429	AAA	821	823	GAA	235;234;235	G,C;A;A	212,1;217;218	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	V151A	NONSYN	451	453	GTA	845	847	GCA	231;232;235	G,A;C,T;A	218,1;219,1;225	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	917	919	TCA	241;243;241	T;C;A	225;227;223	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1046	1048	GTC	210;212;216	G;T;C	192;190;198	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	W257L	NONSYN	769	771	TGG	1163	1165	TTG	226;224;225	T;T;G	211;210;209	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1376	1378	GCA	229;228;231	G;C,A;A	218;214,2;220	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	1	SNP	p	G120K	1	.	.	358	360	AAG	751	753	CGG	209;212;214	C,T;G,A;G,A	201,1;200,1;202,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	1	SNP	p	D121N	0	.	.	361	363	GAC	754	757	CGC	213;218;217	C,G;G,A;C	201,1;204,1;206	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	97.14	porB1b.l6.c4.ctg.1	1658	166.5	1	SNP	p	A121D	1	.	.	361	363	GAC	754	757	CGC	213;218;217	C,G;G,A;C	201,1;204,1;206	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10708	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	5050	211.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2095	2097	CAT	215;216;216	C;A;T	201;201;201	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1126	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	998	112.1	1	SNP	p	V57M	1	.	.	169	171	ATG	553	555	ATG	232;232;232	A;T;G	222;221;221	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
